title: Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model.
abstract: The nasal mucosa is an important arm of the mucosal system since it is often the first point of contact for inhaled antigens. The ineffectiveness of the simple delivery of soluble antigens to mucosal membranes for immunization has stimulated extensive studies in appropriate delivery systems and adjuvants. We have evaluated biphasic lipid vesicles as a novel intranasal (i.n.) delivery system (designated as vaccine targeting adjuvant, VTA) containing bacterial antigens and CpG oligodeoxynucleotides (ODNs). Results show that administration of antigen and CpG ODNs in biphasic lipid vesicles resulted in greater induction of IgA levels in serum (P< 0.05) and mucosal antibody responses such as IgA in nasal secretions and lung (P< 0.01) after immunization with a combined subcutaneous (s.c.)/i.n. as compared to s.c./s.c. approach. Based on antibody responses, VTA formulations were found to be suitable as delivery systems for antigens and CpG ODNs by the intranasal route, resulting in a Th2-type of immune response, characterized by IgG1 and IL-4 production at the systemic level.
authors.affiliation: Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada.
authors.forename: V L
authors.initials: VL
authors.lastname: Alcón
authors.forename: M
authors.initials: M
authors.lastname: Baca-Estrada
authors.forename: M A
authors.initials: MA
authors.lastname: Vega-López
authors.forename: P
authors.initials: P
authors.lastname: Willson
authors.forename: L A
authors.initials: LA
authors.lastname: Babiuk
authors.forename: P
authors.initials: P
authors.lastname: Kumar
authors.forename: M
authors.initials: M
authors.lastname: Foldvari
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000494:pharmacology; D000281:Administration, Intranasal; D000818:Animals; D000906:Antibodies / Q000032:analysis; D000942:Antigens, Bacterial / Q000008:administration & dosage*; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage* / Q000276:immunology; D016503:Drug Delivery Systems; D005260:Female; D018928:Immunity, Mucosal / Q000187:drug effects; D007114:Immunization; D007070:Immunoglobulin A / Q000032:analysis; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D008055:Lipids / Q000276:immunology; D008074:Lipoproteins / Q000008:administration & dosage* / Q000276:immunology; D008168:Lung / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009297:Nasal Mucosa / Q000187:drug effects* / Q000276:immunology; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage* / Q000276:immunology; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000906:Antibodies; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; C408982:CPG-oligonucleotide; D007070:Immunoglobulin A; D008055:Lipids; D008074:Lipoproteins; D009838:Oligodeoxyribonucleotides; C094096:OmlA protein, bacteria; C480625:biphasix-vaccine targeting adjuvant; D015847:Interleukin-4; D007371:Interferon-gamma